- Home
- Products
- Customized ADCs
- ERBB2
- Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC
Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1115)
This ADC product is comprised of an anti-ERBB2 monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); NGL, v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-pr
- Target Entrez Gene ID
- 2064
- Target UniProt ID
- P04626
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Humanized Anti-ERBB2 IgG1-kappa antibody, Pertuzumab
- Generic name
- Pertuzumab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2063)
- Anti-CD28 (lumretuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-2277)
- Anti-LTA (Pateclizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1532)
- Anti-Adenocarcinoma antigen (Technetium (99mTc) pintumomab)-MC-MMAF ADC (CAT#: ADC-W-2116)
- Anti-ST8SIA1 (Mitumomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1781)
- Anti-NCA-90 (Lemalesomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2166)
- Anti-TPBG-Mc-MMAF ADC (CAT#: ADC-W-537)
- Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-MC-MMAF ADC (CAT#: ADC-W-2032)
- Anti-B-cell lymphomas (Detumomab)-SMCC-DM1 ADC (CAT#: ADC-W-2180)
- Anti-TPBG (L443C)-VC-MMAD ADC (CAT#: ADC-W-167)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1115. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1110 | Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-514 | Anti-ERBB2 (Trastuzumab)-VC-DUBA ADC | VC (valine-citrulline) | seco-DUBA (DUocarmycin hydroxyBenzamide Azaindole) |
ADC-W-1114 | Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
CAT# | Product Name | Linker | Payload |
ADC-W-2608 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2586 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2607 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-2574 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2562 | Anti-MSLN (Anetumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2557 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2540 | Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.